Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

Investors are expected to be cautious with Syngene International Limited, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.638000
forwardPE 40.637993
debtToEquity 12.226000
earningsGrowth -0.028000
revenueGrowth 0.110000
grossMargins 0.741240
operatingMargins 0.237820
trailingEps 12.330000
forwardEps 16.850000

Syngene International Limited's current ratio, being 1.638, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, Syngene International Limited is well-equipped to meet its immediate financial obligations without any difficulties.
Syngene International Limited's low Debt-to-Equity ratio reflects the company's conservative use of debt. This shows that it isn't over-leveraged, reducing financial risk and indicating a stable financial structure, which is a positive signal for investors concerned about excessive debt burdens.
SYNGENE's low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for SYNGENE's future profitability.
Positive gross and operating margins for SYNGENE suggest that the company is operating profitably. These margins highlight SYNGENE's efficiency in managing costs while maintaining healthy revenue streams, contributing to its overall financial strength.
Syngene International Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Syngene International Limited's financial performance will improve in the current financial year.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

Syngene International Limited's price projections have gradually risen, indicating growing confidence in the company's prospects. This upward trend suggests that analysts expect Syngene International Limited to continue performing well in the future.

Insider Transactions:

Insider Transactions for SYNGENE
Insider Transactions for SYNGENE


31 Syngene International Limited shares were sold in recent transactions, with market price at 796.8983843403478.No sell transactions were carried out during the period under review.With more buys than sells around SYNGENE's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


SYNGENE has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view SYNGENE as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.